Janssen exec: Commercial potential of Genmab deal will increase
A partnership with Genmab has already led to approval of one potential blockbuster for US drug giant Janssen, but the head of the group’s oncology development sees greater things ahead. “The partnership with Genmab is one I would rank at the very top as a model to follow for our other partnerships”, he says.
BY STEFAN SINGH KAILAY
You would be excused for thinking that the culmination of the collaboration between Janssen and Genmab occurred on November 16 when the FDA approved the two partners’ oncology drug Darzalex for marketing in the US. But that is not the case, the executive in charge of Janssen's clinical oncology development tells MedWatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab CEO is “the happiest man in the world”
For abonnenter
Genmab outlines royalty deal with Janssen
For abonnenter
Genmab has bagged USD 170 million in milestones
For abonnenter
